Kinase inhibitor Mechanism of Action Pharmacokinetics Binding Mode
ChemicalBook > CAS DataBase List > Binimetinib

Binimetinib

Kinase inhibitor Mechanism of Action Pharmacokinetics Binding Mode
Binimetinib Structure
Binimetinib
  • CAS No.606143-89-9
  • Chemical Name:Binimetinib
  • CBNumber:CB82604200
  • Molecular Formula:C17H15BrF2N4O3
  • Formula Weight:441.23
  • MOL File:606143-89-9.mol
Binimetinib Property
  • Melting point >203oC (dec.)
  • Density 1.67
  • storage temp. -20°C
  • solubility Soluble in DMSO (up to at least 25 mg/ml)
  • pka 14.20±0.10(Predicted)
  • form solid
  • color White
  • Stability Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.
  • NCI Dictionary of Cancer Terms binimetinib
  • FDA UNII 181R97MR71
  • NCI Drug Dictionary binimetinib
  • ATC code L01EE03
  • UNSPSC Code 12352200
  • NACRES NA.77
Safety
  • HS Code  :2933998090
Hazard and Precautionary Statements (GHS)
  • Symbol(GHS)
  • Signal wordDanger
  • Hazard statements H360-H362
  • Precautionary statements P201-P260-P263-P264-P270-P308+P313

Binimetinib Chemical Properties,Usage,Production

  • Kinase inhibitor Binimetinib, also known as Mektovi, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor with potential antineoplastic activity.
    Binimetinib, noncompetitive with ATP, binds to and inhibits the activity of MEK1/2. Inhibition of MEK1/2 prevents the activation of MEK1/2 dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling. This may eventually lead to an inhibition of tumor cell proliferation and an inhibition in production of various inflammatory cytokines including interleukin-1, -6 and tumor necrosis factor.
  • Mechanism of Action Binimetinib is a reversible inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activity. MEK proteins are upstream regulators of the extracellular signal-related kinase (ERK) pathway. In vitro, binimetinib inhibited extracellular signal-related kinase (ERK) phosphorylation in cellfree assays as well as viability and MEK-dependent phosphorylation of BRAF-mutant human melanoma cell lines. Binimetinib also inhibited in vivo ERK phosphorylation and tumor growth in BRAF-mutant murine xenograft models.
  • Pharmacokinetics The primary metabolic pathway is glucuronidation with UGT1A1 contributing up to 61% of the binimetinib metabolism. Other pathways of binimetinib metabolism include N-dealkylation, amide hydrolysis, and loss of ethane-diol from the side chain. The active metabolite M3 produced by CYP1A2 and CYP2C19 represents 8.6% of the binimetinib exposure. Following a single oral dose of 45 mg radiolabeled binimetinib, approximately 60% of the circulating radioactivity AUC in plasma was attributable to binimetinib.
  • Binding Mode As shown in the co-crystal structure of binimetinib in complex with BRAF–MEK1 kinases and AMP–PNP (Fig. 1), the imine nitrogen of the benzo[d]imidazole core hydrogen bonds to both the amide NH of Ser212 and amide NH of Val211, and the amide oxygen also forms a hydrogen bond with the primary amine of Lys97. In addition, the terminal hydroxyl group hydrogen bonds to the α-phosphate oxygen of AMP–PNP. Also, the carboxamide side chain oxygen interacts indirectly with the carboxylic acid of Asp208 and AMP–PNP via a water molecule (Fig. 2).
    Figure 1. Co-crystal structure of binimetinib and AMP-PNP with BRAF–MEK1 (PDB ID: 7M0U).Figure 2. Summary of binimetinib and AMP–PNP with BRAF–MEK1. interactions based on an X-ray co-crystal structure.
  • Description Binimetinib (606143-89-9) is a potent (IC50?= 12 nM) and selective allosteric inhibitor of MEK1/2.1,2?Recently approved by the FDA for treatment of melanoma in combination with Encorafenib. Binimetinib has had limited success as monotherapy but has shown promise in combination with other chemotherapeutic agents.3-5
  • Uses MEK 162 is a MEK1/2 inhibitor allowing it to be a effective anti-cancer medication.
  • Definition ChEBI: Binimetinib is a member of the class of benzimidazoles that is 1-methyl-1H-benzimidazole which is substituted at positions 4, 5, and 6 by fluorine, (4-bromo-2-fluorophenyl)nitrilo, and N-(2-hydroxyethoxy)aminocarbonyl groups, respectively. It is a MEK1 and MEK2 inhibitor (IC50= 12 nM). Approved by the FDA for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation in combination with encorafenib. It has a role as an EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor, an antineoplastic agent and an apoptosis inducer. It is a member of benzimidazoles, a member of bromobenzenes, a member of monofluorobenzenes, a hydroxamic acid ester and a secondary amino compound.
  • brand name Mektovi
  • General Description Class: dual threonine/tyrosine kinase; Treatment: melanoma with BRAF mutations; Other name: ARRY-162; Oral bioavailability = 50%; Elimination half-life = 3.5 h; Protein binding = 97%
  • Pharmacokinetics After oral administration, binimetinib is absorbed rapidly, with a median tmax of 1.48 h. Binimetinib is 50% orally bioavailable and exhibits a short elimination half-life of 3.5 h. Consequently, it requires twice-daily dosing regimen. Binimetinib undergoes UGT1A1-mediated glucuronidation, which contributes up to 61% of the overall metabolism. Other metabolic pathways include N-dealkylation, amide hydrolysis, and loss of ethanediol from the side chain.
  • target Primary target: MEK1/2
  • References 1) Lee?et al.?(2010),?Preclinical development of ARRY-162, a potent and selective MEK1/2 inhibitor;?Cancer Res.?70?2515 2) Winski?et al.?(2010),?MEK162 (ARRY-162), a novel MEK ? inhibitor, inhibits tumor growth regardless of KRAS/RAF pathway mutations;?EJC Supplements?8?56 3) Lee?et al.?(2016),?Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models;?Oncotarget?7?39595 4) Gong?et al.?(2017),?MEK162 Enhances Antitumor Activity of 5-Fluorouracil and Trifluridine in KRAS-mutated Human Colorectal Cancer Cell Lines;?Anticancer Res.?37?2831 5) Van Cutsem?et al.?(2019),?Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From Phase III BEACON Colorectal Cancer study;?J. Clin. Oncol.?180?2459
Binimetinib Preparation Products And Raw materials
Raw materials
Preparation Products
Binimetinib Suppliers
Global(208)Suppliers
  • Supplier：
    Henan Tianfu Chemical Co.,Ltd.
  • Tel：+86-0371-55170693<br/>+86-19937530512
  • Email：info@tianfuchem.com
  • Country：China
  • ProdList：21628
  • Advantage：55
  • Supplier：
    career henan chemical co
  • Tel：+86-0371-86658258<br/>+8613203830695
  • Email：sales@coreychem.com
  • Country：China
  • ProdList：29858
  • Advantage：58
  • Supplier：
    Biochempartner
  • Tel：0086-13720134139
  • Email：candy@biochempartner.com
  • Country：CHINA
  • ProdList：965
  • Advantage：58
  • Supplier：
    BOC Sciences
  • Tel：+1-631-485-4226
  • Email：inquiry@bocsci.com
  • Country：United States
  • ProdList：19552
  • Advantage：58
  • Supplier：
    TargetMol Chemicals Inc.
  • Tel：+1-781-999-5354<br/>+1-00000000000
  • Email：marketing@targetmol.com
  • Country：United States
  • ProdList：32159
  • Advantage：58

Related articles

Binimetinib Spectrum
606143-89-9, BinimetinibRelated Search:
  • MAPK
  • API
  • Inhibitors
  • 抑制剂
  • 化学试剂
  • 生物试剂
  • FDA批准的配体
  • 普通产品
  • 化工原料
  • 有机
  • 细胞生物学试剂
  • 原料药
  • 小分子抑制剂
  • 小分子抑制剂，天然产物
  • C17H15BrF2N4O3
  • 化合物BINIMETINIB,10 MM DMSO 溶液
  • BINIMETINIB,MEK1/2抑制剂
  • 比美替尼-[13C2,D4]/精确称量
  • 比美替尼 13CD3
  • 贝(比)美替尼
  • 化合物 BINIMETINIB
  • PERFEMIKER]ARRY-162,98%
  • 贝美替尼相关杂质
  • BINIMETINIB(MEK162) 5级
  • 比美替尼
  • 5-((4-溴-2-氟苯基)氨基)-4-氟-N-(2-羟基乙氧基)-1-甲基-1H-苯并[D]咪唑-6-甲酰胺
  • 化合物PFK-015
  • MEK162 贝美替尼
  • 5-[(4-溴-2-氟苯基)氨基]-4-氟-N-(2-羟基乙氧基)-1-甲基苯并咪唑-6-甲酰胺
  • 星熠艾克
  • 5-[(4-溴-2-氟苯基)氨基]-4-氟-N-(CHEMICALBOOK2-羟基乙氧基)-1-甲基-1H-苯并咪唑-6-甲酰胺
  • 比尼替尼(MEK-162)
  • MEK162,比尼替尼
  • 贝美替尼
  • 比尼替尼
  • 丝裂原活化蛋白激酶抑制剂(MEK162)
  • 5-[(4-溴-2-氟苯基)氨基]-4-氟-N-(2-羟基乙氧基)-1-甲基-1H-苯并咪唑-6-甲酰胺
  • MEK162 5-[(4-溴-2-氟苯基)氨基]-4-氟-N-(2-羟基乙氧基)-1-甲基-1H-苯并咪唑-6-甲酰胺
  • 606143-89-9
  • Binimetinib, 10 mM in DMSO
  • 5-(4-bromo-2-fluoroanilino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide
  • Binimetinib, MEK1/2 inhibitor
  • Valine Impurity 34
  • 6-(4-bromo-2-fluoro-anilino)-7-fluoro-N-(2-hydroxyethoxy)-3-methyl-benzimidazole-5-carboxamide
  • ARRY-438162
  • ARRY-162
  • MEK162
  • Binimetinib-13CD3Q: What is Binimetinib-13CD3 Q: What is the CAS Number of Binimetinib-13CD3
  • 1H-Benzimidazole-6-carboxamide,5-[(4-bromo-2-fluorophenyl)am...
  • Binimetinib ( Mektovi
  • 5-[(4-Bromo-2-fluorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methylbenzimidazole-6-carboxamide
  • Binimetinib(Free Base)
  • Binimetinib USP/EP/BP
  • Binimetinib,MEK162, ARRY-162
  • ARRY 162; ARRY 438162; MEK-162;BINIMETINIB;MEK-162; ARRY-162; ARRY-438162
  • MEK162 (ARRY-438162,Binimetinib)
  • CS-394
  • MEK162, ARRY-162

Home

My